A championship-winning Formula 1 car is on track to speed through downtown Houston in two months. Photo courtesy of Red Bull

Houstonians with a passion for Formula 1 racing have to drive to Austin — and spend a lot of money — to get up close to the innovative cars that reach speeds over 200 miles per hour. That’s all going to change in September.

The Bayou City will be the next host of a Red Bull Showrun. Held on Saturday, September 7 at Discovery Green in downtown Houston, the free event will feature one of Red Bull’s championship-winning RB7 car flying down the streets around the park.

Best of all, it’s completely free to attend. Of course, those who want a great view of the action may purchase $50 grandstand tickets that went on sale this morning.

Held previously in other cities without F1 races such as New York, Dallas, and Washington, D.C., Red Bull uses the Showrun to bring the sport to new fans. Although the sport traces its history to the ‘50s, it has seen a boost in popularity thanks to Formula 1: Drive to Survive, a Netflix show that offers a behind-the-scenes look at key people on each of the 10 teams.

Red Bull’s Formula 1 team is riding particularly high at the moment, having won the Constructors Championship in both 2022 and 2023 on the strength of its car and driver Max Verstappen, who has won three consecutive Drivers’ Championship titles and currently leads the championship this year, too.

"The best part about any Red Bull Showrun is being able to bring Formula One to some fans that have already seen it, but more importantly to some who have never seen Formula One before," David Coulthard, a former Red Bull Racing Grand Prix driver who won 13 races during his 15-year career, said in a statement.

Held from noon to 2 pm, the RB7 car will make a number of trips on the streets, doing doughnuts and burnouts and generally being very fast and loud. In between those runs, the Showrun will feature appearances by other Red Bull athletes and a DJ battle between local legends DJ Mr. Rogers and Chase B, who is the longtime DJ for hip hop star Travis Scott. A complete lineup of appearances will be released at a later date, according to a release.

Fans will also have access to a fan zone with food vendors, F1 racing simulators, Oracle Red Bull Racing merchandise, and other free activities.

For more information, including how to purchase grandstand tickets, visit the event’s website.

------

This article originally ran on CultureMap.

Cadence is investing in Girlstart, an Texas-based nonprofit empowering women in STEM. Photo by Amber Heckler

Tech company revs up support for Texas women in STEM at special F1 event

girls in the driver seat

This week, the worlds of the Lone Star State's tech scene, women in STEM, and Formula 1 collided.

At a private event on Wednesday, October 19, hosted by computational software company Cadence Design Systems, Senior VP of Global HR Tina Jones spoke highly about the pride she felt about Cadence’s company culture and their goals for leaving the world better than they found it in regards to sustainability and giving back to the community. Last week, Cadence was ranked 19th in the 2022 World’s Best Workplaces list.

One of the ways Cadence is giving back to the community is through their Giving Foundation. The foundation is investing in organizations like Girlstart, an Austin-based nonprofit whose mission is to empower young girls’ interest in STEM through educational programs and camps.

“We are determined to make a difference in access to STEM education for those who have been traditionally underrepresented,” Jones said.

Jones announced Cadence would make a $25,000 donation to Girlstart to help further the organization’s mission and to invest in the future women they want to hire. The organization has locations all around Texas, including Dallas, Houston, San Antonio and the Rio Grande Valley, as well as locations in other states like California, Illinois, Washington, and Massachusetts.

“We want to start at Kindergarten and take them through 12th grade and give girls confidence in STEM,” Jones said, “Girlstart is doing that here in Austin, and we’re super proud to be associated with them.”

Girlstart Executive Director Shane Woods was present to accept the donation. During her speech, Woods discussed the importance of broadening young women’s understanding of what STEM is and nurturing a positive mentality so they can stay inspired in their careers.

Part of Woods’ work is to make sure girls know about the different fields that “need STEM eyes” such as biomedical engineering, environmental sustainability, and social justice.

The rest of the event centered around Cadence’s partnership with F1 team McLaren Racing, with three primary team members in attendance – CEO Zak Brown, Team Principal Andreas Seidl, and driver Daniel Ricciardo.

Ricciardo has never been shy about his love for the capital of Texas. He said he was naive about the city when F1 first arrived in 2012, but now it’s one of his favorite places. Circuit of the Americas is one of his favorite challenging tracks, noting the “high speed snake section” at turns three through eight that remind him of similar turns Maggotts and Becketts at Silverstone.

“A circuit that really pushes the car to the limits is fun,” he said, “That’s what I love about Austin.”

McLaren’s partnership with Cadence is significant for more than their expertise with computational fluid dynamics. Both companies share similar goals in regards to environmental sustainability and equality. In 2021, McLaren became the first F1 team to release an annual sustainability report, showing they are on track to achieve carbon net zero by 2040. In that same year, they announced Emma Gilmour would be the team’s first female racing driver, racing in Extreme E alongside Tanner Foust.

When asked about what they predict the next 10 years of Formula 1 will look like, Brown and Ricciardo agreed they hoped to see F1 still thriving and at the pinnacle of motorsport, while also giving recognition to the rise of other motorsports. Brown said he would like to see the introduction of rotational races in other countries.

“We have a lot of countries that want races. We’re at a maximum schedule of 24…I would love to see us in 30 countries, but 24 times a year. You might land on 18 permanent races and then have 10 that rotate every two years or something like that,” Brown said. “I think there’s room to grow the sport globally."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”